

Anticoagulation Forum Conference Highlights 2019

Date of CE Release: July 30, 2019

Date of CE Expiration: July 30, 2021

Location: Online

Acknowledgement of In-Kind Commercial Support

No in-kind commercial support was received for this educational activity.

Satisfactory Completion

Learners must listen to each self-directed audio recording while following along with the visual slides and complete an evaluation form to receive a certificate of completion.

If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.

Physicians / Nurses / Pharmacists



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Anticoagulation Forum. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

Amedco LLC designates this enduring activity for a maximum of 2.5 *AMA PRA Category 1 Credits*™ for physicians and 2.5 contact hours for nurses and 2.5 of knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.

Objectives - After completing this program you should be able to:

1. Determine appropriate antithrombotic treatment by disease state including optimization of drug therapy, duration and combinations of different agents, and best ways to transition between therapies
2. Design ways to improve safety and quality of antithrombotic therapy.

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest, and have been resolved. (C7 SCS 6.1---6.2, 6.5) If their name is not listed below, they disclosed that they had no financial relationships with a commercial interest.

First Name	Last Name	CI	Relationship
David	Garcia	Daiichi Sankyo	Grants/ Research
		Janssen	Consultant Fees
Lynn	Oertel	Roche, Portola Pharmaceuticals	Consultant Fees
Sara	Vazquez	American Society of Hematology 2018 Education Session Manuscript	Honorarium
		UptoDate	Consultant Fees